Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

Integrating the Hierarchical Taxonomy of Psychopathology (HiTOP) into clinical practice.

Ruggero CJ, Kotov R, Hopwood CJ, First M, Clark LA, Skodol AE, Mullins-Sweatt SN, Patrick CJ, Bach B, Cicero DC, Docherty A, Simms LJ, Bagby RM, Krueger RF, Callahan JL, Chmielewski M, Conway CC, De Clercq B, Dornbach-Bender A, Eaton NR, Forbes MK, Forbush KT, Haltigan JD, Miller JD, Morey LC, Patalay P, Regier DA, Reininghaus U, Shackman AJ, Waszczuk MA, Watson D, Wright AGC, Zimmermann J.

J Consult Clin Psychol. 2019 Dec;87(12):1069-1084. doi: 10.1037/ccp0000452.

2.

Evidence, values, and funding decisions in Canadian cancer systems.

Peacock SJ, Regier DA, Raymakers AJN, Chan KKW.

Healthc Manage Forum. 2019 Nov;32(6):293-298. doi: 10.1177/0840470419870831. Epub 2019 Sep 4.

PMID:
31645144
3.

Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review.

Raymakers AJN, Regier DA, Peacock SJ.

Cancer. 2019 Sep 23. doi: 10.1002/cncr.32455. [Epub ahead of print]

PMID:
31544234
4.

Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study.

Regier DA, Veenstra DL, Basu A, Carlson JJ.

Pharmacoeconomics. 2019 Sep 6. doi: 10.1007/s40273-019-00834-0. [Epub ahead of print]

PMID:
31489595
5.

The Aspirations for a Paradigm Shift in DSM-5: An Oral History.

Zachar P, Regier DA, Kendler KS.

J Nerv Ment Dis. 2019 Sep;207(9):778-784. doi: 10.1097/NMD.0000000000001063.

PMID:
31464988
6.

Clinical exome sequencing vs. usual care for hereditary colorectal cancer diagnosis: A pilot comparative effectiveness study.

Niu X, Amendola LM, Hart R, Bennette CS, Heagerty P, Horike-Pyne M, Trinidad SB, Rosenthal EA, Comstock B, Nefcy C, Hisama FM, Bennett RL, Grady WM, Gallego CJ, Tarczy-Hornoch P, Fullerton SM, Burke W, Regier DA, Dorschner MO, Shirts BH, Robertson PD, Nickerson DA, Patrick DL, Jarvik GP, Veenstra DL.

Contemp Clin Trials. 2019 Sep;84:105820. doi: 10.1016/j.cct.2019.105820. Epub 2019 Aug 7.

PMID:
31400517
7.

Validation of a Cyclic Algorithm to Proxy Number of Lines of Systemic Cancer Therapy Using Administrative Data.

Weymann D, Costa S, Regier DA.

JCO Clin Cancer Inform. 2019 Aug;3:1-10. doi: 10.1200/CCI.19.00022.

8.

Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs.

Costa S, Bentley C, Regier DA, McTaggart-Cowan H, Mitton C, Burgess MM, Peacock SJ.

BMC Public Health. 2019 Jul 22;19(1):977. doi: 10.1186/s12889-019-7303-2.

9.

Allocating healthcare resources to genomic testing in Canada: latest evidence and current challenges.

Weymann D, Dragojlovic N, Pollard S, Regier DA.

J Community Genet. 2019 Jul 5. doi: 10.1007/s12687-019-00428-5. [Epub ahead of print]

PMID:
31273679
10.

The EORTC QLU-C10D: The Canadian Valuation Study and Algorithm to Derive Cancer-Specific Utilities From the EORTC QLQ-C30.

McTaggart-Cowan H, King MT, Norman R, Costa DSJ, Pickard AS, Regier DA, Viney R, Peacock SJ.

MDM Policy Pract. 2019 Apr 13;4(1):2381468319842532. doi: 10.1177/2381468319842532. eCollection 2019 Jan-Jun.

11.

Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia.

Costa S, Scott DW, Steidl C, Peacock SJ, Regier DA.

Curr Oncol. 2019 Apr;26(2):108-113. doi: 10.3747/co.26.4565. Epub 2019 Apr 1.

12.

The Feelings About genomiC Testing Results (FACToR) Questionnaire: Development and Preliminary Validation.

Li M, Bennette CS, Amendola LM, Ragan Hart M, Heagerty P, Comstock B, Tarczy-Hornoch P, Fullerton SM, Regier DA, Burke W, Trinidad SB, Jarvik GP, Veenstra DL, Patrick DL.

J Genet Couns. 2019 Apr;28(2):477-490. doi: 10.1007/s10897-018-0286-9. Epub 2018 Dec 14.

PMID:
30964586
13.

Balancing uncertainty with patient autonomy in precision medicine.

Pollard S, Sun S, Regier DA.

Nat Rev Genet. 2019 May;20(5):251-252. doi: 10.1038/s41576-019-0111-9. No abstract available.

PMID:
30872766
14.

Progress in achieving quantitative classification of psychopathology.

Krueger RF, Kotov R, Watson D, Forbes MK, Eaton NR, Ruggero CJ, Simms LJ, Widiger TA, Achenbach TM, Bach B, Bagby RM, Bornovalova MA, Carpenter WT, Chmielewski M, Cicero DC, Clark LA, Conway C, DeClercq B, DeYoung CG, Docherty AR, Drislane LE, First MB, Forbush KT, Hallquist M, Haltigan JD, Hopwood CJ, Ivanova MY, Jonas KG, Latzman RD, Markon KE, Miller JD, Morey LC, Mullins-Sweatt SN, Ormel J, Patalay P, Patrick CJ, Pincus AL, Regier DA, Reininghaus U, Rescorla LA, Samuel DB, Sellbom M, Shackman AJ, Skodol A, Slade T, South SC, Sunderland M, Tackett JL, Venables NC, Waldman ID, Waszczuk MA, Waugh MH, Wright AGC, Zald DH, Zimmermann J.

World Psychiatry. 2018 Oct;17(3):282-293. doi: 10.1002/wps.20566.

15.

Using "Big Data" in the Cost-Effectiveness Analysis of Next-Generation Sequencing Technologies: Challenges and Potential Solutions.

Wordsworth S, Doble B, Payne K, Buchanan J, Marshall DA, McCabe C, Regier DA.

Value Health. 2018 Sep;21(9):1048-1053. doi: 10.1016/j.jval.2018.06.016. Epub 2018 Aug 17. Erratum in: Value Health. 2019 Apr;22(4):502.

16.

Valuation of Health and Nonhealth Outcomes from Next-Generation Sequencing: Approaches, Challenges, and Solutions.

Regier DA, Weymann D, Buchanan J, Marshall DA, Wordsworth S.

Value Health. 2018 Sep;21(9):1043-1047. doi: 10.1016/j.jval.2018.06.010. Epub 2018 Aug 18. Review. Erratum in: Value Health. 2019 Apr;22(4):502.

17.

Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions.

Phillips KA, Deverka PA, Marshall DA, Wordsworth S, Regier DA, Christensen KD, Buchanan J.

Value Health. 2018 Sep;21(9):1033-1042. doi: 10.1016/j.jval.2018.06.017. Epub 2018 Aug 8. Review. Erratum in: Value Health. 2019 Mar;22(3):383.

18.

The Feelings About genomiC Testing Results (FACToR) Questionnaire: Development and Preliminary Validation.

Li M, Bennette CS, Amendola LM, Ragan Hart M, Heagerty P, Comstock B, Tarczy-Hornoch P, Fullerton SM, Regier DA, Burke W, Trinidad SB, Jarvik GP, Veenstra DL, Patrick DL.

J Genet Couns. 2018 Sep 1. doi: 10.1007/s10897-018-0286-9. [Epub ahead of print]

PMID:
30173308
19.

Cancer drug expenditure in British Columbia and Saskatchewan: a trend analysis.

Pataky R, Tran DA, Coronado A, Alvi R, Boehm D, Regier DA, Peacock S.

CMAJ Open. 2018 Jul 27;6(3):E292-E299. doi: 10.9778/cmajo.20170161. Print 2018 Jul-Sep.

20.

Patient preferences for massively parallel sequencing genetic testing of colorectal cancer risk: a discrete choice experiment.

Weymann D, Veenstra DL, Jarvik GP, Regier DA.

Eur J Hum Genet. 2018 Sep;26(9):1257-1265. doi: 10.1038/s41431-018-0161-z. Epub 2018 May 25.

21.

Uncertainty as a Driver of Mental Disorder Diagnostic Strategies.

Regier DA.

Psychiatry. 2017 Winter;80(4):309-314. doi: 10.1080/00332747.2017.1397453. No abstract available.

PMID:
29466108
22.

Pregnancy planning preferences among people and couples affected by human immunodeficiency virus: Piloting a discrete choice experiment.

Loutfy M, Kennedy VL, Sanandaji M, Barry F, Ongoiba F, Muchenje M, Tharao W, Regier DA.

Int J STD AIDS. 2018 Mar;29(4):382-391. doi: 10.1177/0956462417728188. Epub 2017 Sep 5.

PMID:
28872418
23.

Assessment of Individual Patient Preferences to Inform Clinical Practice.

Whitty JA, Fraenkel L, Saigal CS, Groothuis-Oudshoorn CGM, Regier DA, Marshall DA.

Patient. 2017 Aug;10(4):519-521. doi: 10.1007/s40271-017-0254-8. No abstract available.

PMID:
28597378
24.

The cost and cost trajectory of whole-genome analysis guiding treatment of patients with advanced cancers.

Weymann D, Laskin J, Roscoe R, Schrader KA, Chia S, Yip S, Cheung WY, Gelmon KA, Karsan A, Renouf DJ, Marra M, Regier DA.

Mol Genet Genomic Med. 2017 Mar 12;5(3):251-260. doi: 10.1002/mgg3.281. eCollection 2017 May.

25.

The Girls-Only HPV Vaccination Program in British Columbia, Canada: A Qualitative Study Exploring Expert Informants' Perspectives of Input From the Public.

McTaggart-Cowan H, Bentley C, Ogilvie G, Regier DA, Peacock SJ.

J Obstet Gynaecol Can. 2017 Sep;39(9):726-727. doi: 10.1016/j.jogc.2017.03.116. Epub 2017 May 13. No abstract available.

PMID:
28511920
26.

Exploring the Factors Considered by People Living with HIV and Their Partners during Preconception.

Kennedy VL, Collins M, Yudin MH, Serghides L, Walmsley S, Angel JB, Ongoiba F, Powis J, Smaill F, Tharao W, Rachlis A, Silverman M, Sandre R, Regier DA, Loutfy M.

J Int Assoc Provid AIDS Care. 2017 May/Jun;16(3):239-246. doi: 10.1177/2325957416682089. Epub 2016 Dec 19.

PMID:
28485707
27.

The Hierarchical Taxonomy of Psychopathology (HiTOP): A dimensional alternative to traditional nosologies.

Kotov R, Krueger RF, Watson D, Achenbach TM, Althoff RR, Bagby RM, Brown TA, Carpenter WT, Caspi A, Clark LA, Eaton NR, Forbes MK, Forbush KT, Goldberg D, Hasin D, Hyman SE, Ivanova MY, Lynam DR, Markon K, Miller JD, Moffitt TE, Morey LC, Mullins-Sweatt SN, Ormel J, Patrick CJ, Regier DA, Rescorla L, Ruggero CJ, Samuel DB, Sellbom M, Simms LJ, Skodol AE, Slade T, South SC, Tackett JL, Waldman ID, Waszczuk MA, Widiger TA, Wright AGC, Zimmerman M.

J Abnorm Psychol. 2017 May;126(4):454-477. doi: 10.1037/abn0000258. Epub 2017 Mar 23. Review.

PMID:
28333488
28.

A time-and-motion approach to micro-costing of high-throughput genomic assays.

Costa S, Regier DA, Meissner B, Cromwell I, Ben-Neriah S, Chavez E, Hung S, Steidl C, Scott DW, Marra MA, Peacock SJ, Connors JM.

Curr Oncol. 2016 Oct;23(5):304-313. Epub 2016 Oct 25.

29.

Utility Estimates of Disease-Specific Health States in Prostate Cancer from Three Different Perspectives.

Gries KS, Regier DA, Ramsey SD, Patrick DL.

Appl Health Econ Health Policy. 2017 Jun;15(3):375-384. doi: 10.1007/s40258-016-0282-x.

PMID:
27704390
30.
31.

Cost-Effectiveness Analysis of Using Loss of Heterozygosity to Manage Premalignant Oral Dysplasia in British Columbia, Canada.

Cromwell I, Regier DA, Peacock SJ, Poh CF.

Oncologist. 2016 Sep;21(9):1099-106. doi: 10.1634/theoncologist.2015-0433. Epub 2016 Jul 11.

32.

Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia.

Cressman S, Karsan A, Hogge DE, McPherson E, Bolbocean C, Regier DA, Peacock SJ.

Br J Haematol. 2016 Aug;174(4):526-35. doi: 10.1111/bjh.14076. Epub 2016 Apr 21.

33.

Preferences for Prostate Cancer Outcomes: A Comparison of the Patient Perspective, the General Population Perspective, and a Population at Risk for Prostate Cancer.

Gries KS, Regier DA, Ramsey SD, Patrick DL.

Value Health. 2016 Mar-Apr;19(2):218-25. doi: 10.1016/j.jval.2015.11.012. Epub 2016 Jan 14.

34.

Public Perceptions of the Benefits and Risks of Newborn Screening.

Miller FA, Hayeems RZ, Bombard Y, Cressman C, Barg CJ, Carroll JC, Wilson BJ, Little J, Allanson J, Chakraborty P, Giguère Y, Regier DA.

Pediatrics. 2015 Aug;136(2):e413-23. doi: 10.1542/peds.2015-0518. Epub 2015 Jul 13.

35.

Societal preferences for the return of incidental findings from clinical genomic sequencing: a discrete-choice experiment.

Regier DA, Peacock SJ, Pataky R, van der Hoek K, Jarvik GP, Hoch J, Veenstra D.

CMAJ. 2015 Apr 7;187(6):E190-E197. doi: 10.1503/cmaj.140697. Epub 2015 Mar 9.

36.

Parents' willingness to pay for biologic treatments in juvenile idiopathic arthritis.

Burnett HF, Ungar WJ, Regier DA, Feldman BM, Miller FA.

Value Health. 2014 Dec;17(8):830-7. doi: 10.1016/j.jval.2014.08.2668. Epub 2014 Nov 6.

37.

Public engagement in priority-setting: results from a pan-Canadian survey of decision-makers in cancer control.

Regier DA, Bentley C, Mitton C, Bryan S, Burgess MM, Chesney E, Coldman A, Gibson J, Hoch J, Rahman S, Sabharwal M, Sawka C, Schuckel V, Peacock SJ.

Soc Sci Med. 2014 Dec;122:130-9. doi: 10.1016/j.socscimed.2014.10.038. Epub 2014 Oct 18.

PMID:
25441325
38.

Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada.

Cressman S, Lam S, Tammemagi MC, Evans WK, Leighl NB, Regier DA, Bolbocean C, Shepherd FA, Tsao MS, Manos D, Liu G, Atkar-Khattra S, Cromwell I, Johnston MR, Mayo JR, McWilliams A, Couture C, English JC, Goffin J, Hwang DM, Puksa S, Roberts H, Tremblay A, MacEachern P, Burrowes P, Bhatia R, Finley RJ, Goss GD, Nicholas G, Seely JM, Sekhon HS, Yee J, Amjadi K, Cutz JC, Ionescu DN, Yasufuku K, Martel S, Soghrati K, Sin DD, Tan WC, Urbanski S, Xu Z, Peacock SJ; Pan-Canadian Early Detection of Lung Cancer Study Team.

J Thorac Oncol. 2014 Oct;9(10):1449-58. doi: 10.1097/JTO.0000000000000283.

39.

Constant-sum paired comparisons for eliciting stated preferences: a tutorial.

Skedgel C, Regier DA.

Patient. 2015 Apr;8(2):155-63. doi: 10.1007/s40271-014-0077-9.

PMID:
25038741
40.

Comparative effectiveness of next generation genomic sequencing for disease diagnosis: design of a randomized controlled trial in patients with colorectal cancer/polyposis syndromes.

Gallego CJ, Bennette CS, Heagerty P, Comstock B, Horike-Pyne M, Hisama F, Amendola LM, Bennett RL, Dorschner MO, Tarczy-Hornoch P, Grady WM, Fullerton SM, Trinidad SB, Regier DA, Nickerson DA, Burke W, Patrick DL, Jarvik GP, Veenstra DL.

Contemp Clin Trials. 2014 Sep;39(1):1-8. doi: 10.1016/j.cct.2014.06.016. Epub 2014 Jul 3.

41.

Feasibility and acceptability of the DSM-5 Field Trial procedures in the Johns Hopkins Community Psychiatry Programs.

Clarke DE, Wilcox HC, Miller L, Cullen B, Gerring J, Greiner LH, Newcomer A, McKitty MV, Regier DA, Narrow WE.

Int J Methods Psychiatr Res. 2014 Jun;23(2):267-78. doi: 10.1002/mpr.1419. Epub 2014 Feb 25.

42.

APIRE Practice Research Network: accomplishments, challenges, and lessons learned.

West JC, Mościcki EK, Duffy FF, Wilk JE, Countis L, Narrow WE, Regier DA.

Psychother Res. 2015;25(1):152-65. doi: 10.1080/10503307.2013.868948. Epub 2014 Jan 6.

PMID:
24386950
43.

Two views on the new DSM-5: DSM-5: a diagnostic guide relevant to both primary care and psychiatric practice.

Kupfer DJ, Kuhl EA, Regier DA.

Am Fam Physician. 2013 Oct 15;88(8):Online. No abstract available.

44.

Axis V: essential supplement to the DSM-5: in reply.

Narrow WE, Regier DA.

Psychiatr Serv. 2013 Oct;64(10):1066-7. doi: 10.1176/appi.ps.6401006. No abstract available.

PMID:
24081412
45.

Exploring colposcopists' attitudes towards use of HPV testing as a primary screening tool for cervical cancer in British Columbia.

Regier DA, van der Hoek K, Ogilvie G, Smith L, Henwood E, Miller DM, McTaggart-Cowan H, Peacock SJ.

J Obstet Gynaecol Can. 2013 Jul;35(7):657-63.

PMID:
23876645
46.

Response to Barglow letter.

Regier DA, Friedman MJ, Kraemer HC, Narrow WE, Kupfer DJ.

Am J Psychiatry. 2013 Jun;170(6):680-1. No abstract available.

PMID:
23875197
47.

Testing DSM-5 in routine clinical practice settings: feasibility and clinical utility.

Mościcki EK, Clarke DE, Kuramoto SJ, Kraemer HC, Narrow WE, Kupfer DJ, Regier DA.

Psychiatr Serv. 2013 Oct;64(10):952-60. doi: 10.1176/appi.ps.201300098.

PMID:
23852272
48.

Sustaining practice change one year after completion of the national depression management leadership initiative.

Chung H, Duffy FF, Katzelnick DJ, Williams MD, Trivedi MH, Rae DS, Regier DA.

Psychiatr Serv. 2013 Jul 1;64(7):703-6. doi: 10.1176/appi.ps.201200227.

PMID:
23821170
49.

Expression of antibodies using single open reading frame (sORF) vector design: Demonstration of manufacturing feasibility.

Gion WR, Davis-Taber RA, Regier DA, Fung E, Medina L, Santora LC, Bose S, Ivanov AV, Perilli-Palmer BA, Chumsae CM, Matuck JG, Kunes YZ, Carson GR.

MAbs. 2013 Jul-Aug;5(4):595-607. doi: 10.4161/mabs.25161. Epub 2013 May 31.

50.

The DSM-5: Classification and criteria changes.

Regier DA, Kuhl EA, Kupfer DJ.

World Psychiatry. 2013 Jun;12(2):92-8. doi: 10.1002/wps.20050.

Supplemental Content

Loading ...
Support Center